Symbiotec Pharmalab IPO
Market Sentiment
IPO Details
Market Lot Size
IPO Reservation
Return Estimator (GMP*)
Financial Analysis
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 723.33 | 755.98 | 872.26 |
| Expense | 590.99 | 608.85 | 709.90 |
| Profit (PAT) | 100.06 | 96.79 | 109.90 |
| Total Assets | 1,294.79 | 1,579.65 | 1,780.79 |
| Company | EPS | P/E | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Concord Biotech Limited | 24.78 | 61.07 | 14.00 | - | 1,054.90 Cr |
| Divi’s Laboratories Limited | 96.75 | 87.80 | 16.50 | 631.00 | 10,560.00 Cr |
| Cohance Lifesciences Limited | 4.69 | 95.02 | 7.00 | - | 2,268.55 Cr |
| Laurus Labs Limited | 16.47 | 109.36 | 16.80 | - | 6,812.90 Cr |
Promoters: Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP
Strengths & Risks
- Strong grey-market premium — +22% over the issue price.
- Revenue grew 15% in the latest reported year.
- Solid profit margin — 12.6%.
- Largely an offer for sale — most proceeds go to selling shareholders, not the company.
Compiled from this issue's live GMP, subscription, valuation and financial data, and updated as those figures change. Informational only — not investment advice. Always read the RHP before applying.
Company Information
| Purpose | Amount (Cr) |
|---|---|
| Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company | 112.50 |
| General corporate purposes | - |
Resources & Documents
Symbiotec Pharmalab Ltd., 385/2,, Pigdamber, Rau,, Mhow,, Indore, Madhya Pradesh, 453331
Symbiotec Pharmalab has set a price band of Rs 938–Rs 988 per share for an issue size of Rs 1,757 crore. The Mainboard issue is scheduled to open for subscription on August 24, 2026 — 4 days from now.
The issue is promoted by Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP with JM Financial Ltd., Avendus Capital Pvt. Ltd., Motilal Oswal Investment Advisors Ltd., Nomura Financial Advisory & Securities (India) Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Co… (Rs 113 crore) and General corporate purposes.
Grey market is quoting a premium of +Rs 220 (+22.3% over issue price).
On fundamentals, the company is posting revenue growth of 15.4%, a profit margin of 12.6%, return on equity of 11.2% in its most recent reported period. Listed peers in this segment include Concord Biotech Limited (P/E 61.07x) and Divi’s Laboratories Limited (P/E 87.80x) — useful reference points when evaluating the issue's pricing relative to where the broader sector are trading.
Our data-driven engine currently flags this issue as a Subscribe call — the composite picture tilts favourable, though not without some caveats. All figures below — GMP history, subscription tiers, financials and peers — are aggregated from public disclosures. Always apply through your own broker after reading the RHP.
Symbiotec Pharmalab IPO GMP — What It Means
The latest grey market premium for Symbiotec Pharmalab IPO is ₹220 (+22.3%). GMP is an unofficial, dealer-quoted figure that hints at expected listing-day demand — it is not a guaranteed listing price. For Symbiotec Pharmalab it should be read alongside the subscription numbers and the company's fundamentals, since grey-market premiums can swing sharply during the bidding window.
See the full Symbiotec Pharmalab GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
No comments yet. Be the first to share your opinion!